TCERG1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4699731	1.00	2/20
SCHEMBL4697866	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL4699947	0.83	2/20
SCHEMBL4699140	0.80	2/20
SCHEMBL4922941	0.80	2/20
SCHEMBL4916509	0.78	2/20
SCHEMBL4700123	0.77	2/20
SCHEMBL4698636	0.76	2/20
SCHEMBL4914334	0.76	2/20
SCHEMBL4917606	0.76	2/20
SCHEMBL4908396	0.74	2/20
SCHEMBL4699183	0.74	2/20
SCHEMBL4914310	0.73	2/20
SCHEMBL4915098	0.73	2/20
SCHEMBL4696222	0.72	2/20
SCHEMBL4701699	0.70	2/20
SCHEMBL4698169	0.70	2/20
SCHEMBL4696537	0.68	2/20
SCHEMBL4920392	0.66	2/20

Clinical trials — most relevant to TCERG1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Epirubicin, Docetaxel, and Capecitabine in Treating Women With Stage IIIA or Stage IIIB Breast Cancer	PHASE2	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
PBA Use for Treatment of ATF6-/- Patients	EARLY_PHASE1	SUSPENDED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
Serum Betatrophin Levels and Its Influencing Factors in Patients With Hyperthyroidism	nan	UNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
The Influence of Genetic Variations in ELAPOR1 or ELAPOR2 on Insulin Secretion and Glucose Regulation in Humans	nan	UNKNOWN
EKLF Gene Expression in β-thalassemia	nan	NOT_YET_RECRUITING
Identification of Viable Human Embryos Using Three Different Methods	nan	COMPLETED
miRNA as a Growth Plate Marker After GH	nan	UNKNOWN
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING
Mapping Novel Disease Genes for Dilated Cardiomyopathy	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Recombinant Interferon Alfa-2b in Treating Patients With Melanoma	nan	COMPLETED
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Whole Exome and Whole Genome Sequencing for Genotyping of Inherited and Congenital Eye Conditions	nan	RECRUITING
Child Development and Genetic Biomarkers(II): Gene Verification and Data Integration	nan	UNKNOWN
Prevalence of a Non-Expressing 11B Mutation in Aka Peoples of the Central African Republic	nan	COMPLETED
Telomeres Length in Israeli Fibrotic ILD Patients	nan	ENROLLING_BY_INVITATION
Human Epilepsy Genetics--Neuronal Migration Disorders Study	nan	RECRUITING
Finding Genes With NGS Techniques in Whom Mutations Cause Neurological Diseases	nan	UNKNOWN
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a TCERG1 binder may also engage these)

Protein	Name	Similarity
Q8CGF7	—	1.000	Q8CGF7 →
Q63627	—	0.988	Q63627 →
Q960X8	—	0.987	Q960X8 →
P34600	—	0.986	P34600 →
SMARCC2	SWI/SNF complex subunit SMARCC2	0.986	landscape →
O95104	—	0.986	O95104 →
Q9VIV2	—	0.986	Q9VIV2 →
Q9ESU6	—	0.985	Q9ESU6 →
B2RY56	—	0.984	B2RY56 →
P97496	—	0.984	P97496 →
Q9LV14	—	0.984	Q9LV14 →
Q9N3S4	—	0.983	Q9N3S4 →
SMARCC1	SWI/SNF complex subunit SMARCC1	0.983	landscape →
Q2T9I5	—	0.983	Q2T9I5 →
Q641G3	—	0.983	Q641G3 →
U2SURP	U2 snRNP-associated SURP motif-containing protein	0.983	landscape →
BRD4	Bromodomain-containing protein 4	0.983	landscape →
Q8TC92	—	0.983	Q8TC92 →
Q32NW2	—	0.983	Q32NW2 →
Q6GLQ4	—	0.983	Q6GLQ4 →
P41846	—	0.983	P41846 →
Q99LI8	—	0.983	Q99LI8 →
Q0V8S0	—	0.982	Q0V8S0 →
Q8CH02	—	0.982	Q8CH02 →
Q6PGA0	—	0.982	Q6PGA0 →
B3MJ69	—	0.982	B3MJ69 →
Q8K0V4	—	0.982	Q8K0V4 →
Q6PDG5	—	0.982	Q6PDG5 →
Q9UPN6	—	0.982	Q9UPN6 →
Q7TSH6	—	0.982	Q7TSH6 →